AAMP 1

Drug Profile

AAMP 1

Latest Information Update: 29 Apr 2008

Price : $50

At a glance

  • Originator National Institutes of Health (USA)
  • Class Anticoagulants; Proteins
  • Mechanism of Action Heparin modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Haematological disorders

Most Recent Events

  • 23 Sep 1998 No-Development-Reported for Haematological disorders in USA (Parenteral)
  • 05 Jul 1996 New profile
  • 05 Jul 1996 Preclinical development for Haematological disorders in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top